The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

abmtx.com

Founded Year

2015

Stage

Series B | Alive

Total Raised

$51.1M

Last Raised

$30M | 4 mos ago

About ABMTX

ABMTX is a drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer.

ABMTX Headquarter Location

780 Cailun Road Suite 809

Shanghai, Shanghai, 201203,

China

86 21 50273126

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ABMTX

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ABMTX is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest ABMTX News

ABM Therapeutics Receives IND Approval In China For BRAF Inhibitor ABM-1310

Nov 30, 2021

ABM Therapeutics Receives IND Approval In China For BRAF Inhibitor ABM-1310 SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation... Author: SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China. This is the first clinical candidate and IND approval obtained by ABM Therapeutics in China. ABM-1310 is a brain-penetrant BRAF inhibitor. Due to its high selectivity and optimal physicochemical properties, as well as superior efficacies and high margin of safety in preclinical models, it is expected to solve issues, such as brain metastasis, that are associated with marketed drugs. The Phase 1 trials will be a multi-center, open-label study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. The primary goal of the study is to determine the optimal dose for Phase 1b/2 studies. The company started an ongoing Phase 1 safety trial in the United States in June of 2020. "This is excellent progress for ABM. I really appreciate the team, including members from our supporting CRO, for all their highly efficient and superbly executed hard work. This first IND approval in China is another milestone in the development of ABM-1310, which further validates ABM's capabilities of independent R&D innovation and technological excellence," said Dr. Chen Chen, founder and CEO of ABM Therapeutics. "Due to the blood-brain barrier (BBB), most anti-cancer drugs have poor brain penetration, resulting in limited efficacy on the brain lesion. It is an indisputable fact that many cancer patients are affected by brain metastases, but current treatment options are rare. It is a challenge to develop brain-penetrant anti-cancer drugs, but there is certainly a highly unmet medical need. ABM-1310 is a novel small molecule with high water solubility, cell permeability, and selectivity. We will begin clinical development at full throttle in China with the hope of bringing the potential therapeutic benefits to patients in the near future." As a leading company with an emphasis on small molecules with good cell/brain permeability to address cancer metastases, particularly brain metastases, ABM has a broad and robust proprietary pipeline based on its brain medicine R&D platform. The company looks forward to further collaboration with investigators, clinical sites, big pharma and biotech companies. About ABM Therapeutics ABM Therapeutics is a clinical-stage biopharmaceutical company with a focus on the small molecule research and development of novel drugs for the treatment of cancers. ABM has been building its broad and robust proprietary pipeline via its unique BPKdd TM (Brain-Penetrant Kinase Drug Discovery Platform). ABM's pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet need for treating Glioblastoma (GBM) and various metastases in the brain. ABM Therapeutic's first clinical candidate, ABM-1310, was granted IND approval by the FDA on November 29, 2019 (Clinical trial information: NCT04190628 ). More information about ABM's ongoing ABM-1310 trial in the US is available at www.ClinicalTrials.gov and on the company website at www.abmtx.com .

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.